Logo.jpg
Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers
30 janv. 2023 09h15 HE | Aesther Healthcare Acquisition Corp.
Results outline novel bispecific antibody approach that generates strong anti-tumor response in malignant melanoma, holding potential to control important pathways in multiple cancer types Ocean...
TIP_link_300x300.jpg
T-Cell Therapy Market Size to Hit $21+ Billion with Booming CAGR Value of 20.7% by 2028 | The Insight Partners
20 oct. 2022 09h22 HE | The Insight Partners
New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "T-cell Therapy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact and...
Straits Research Pvt Ltd
Next-Generation Gynecological Cancer Diagnostics Market Size is projected to reach USD 5.45 Billion by 2030, growing at a CAGR of 10.68%: Straits Research
15 août 2022 13h50 HE | Straits Research
New York, United States, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Uterine, ovarian, and cervical cervix cancers are the most common in women. Cervical cancer ranks fourth among women's...
Picture1.jpg
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
15 juin 2022 07h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Qualigen-Logo-Tag.png
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
20 mai 2022 09h15 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Logo.png
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
19 août 2021 09h27 HE | Vyant Bio, Inc.
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...
trypf.png
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking
28 juil. 2021 08h30 HE | Tryp Therapeutics Inc.
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
LOGO.jpg
Vivos Inc Extends it Intellectual Property Protection
01 déc. 2020 09h30 HE | Vivos Inc.
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent...
Reports and Data.jpeg-01
Peptide Therapeutics Market To Reach USD 50.60 Billion By 2026 | Reports and Data
23 mars 2020 15h00 HE | Reports and Data
New York, March 23, 2020 (GLOBE NEWSWIRE) -- The global Peptide Therapeutics market was valued at USD 25.35 billion in 2018 and is expected to reach USD 50.60 billion by the year 2026, at a CAGR of...
Logo.jpg
Celsion Corporation Announces Issuance of New Patent for ThermoDox®
17 avr. 2019 08h00 HE | Celsion CORP
 Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox®           Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J,...